Organization & Developments: Astellas

Financial Highlights

Revenue increased 22% year-on-year to ¥1.453 trillion

Core operating profit rose 44% year-on-year to ¥297.5 billion

Full year forecast revised upward: revenue by ¥100 billion and core operating profit by ¥70 billion

Strategic Brands expanded to over ¥240 billion with growth of about ¥140 billion year-on-year

SG&A ratio improved by 4 percentage points due to SMT (sustainable margin transformation) initiatives

Key Product Performance

XTANDI: Global sales increased to ¥703.1 billion, up 26% year-on-year

PADCEV: Global sales increased to ¥117 billion, up 110% year-on-year

IZERVAY: Sales expanded to ¥44.4 billion since launch less than 1.5 years ago

VEOZAH: Sales reached ¥24.4 billion with steady growth

VYLOY: Global sales reached ¥4.9 billion since launch in Japan in June

XOSPATA: Global sales increased to ¥53.1 billion, up 29% year-on-year

Notable Developments

IZERVAY: FDA set PDUFA date of February 26 for label update to extend treatment beyond 12 months

VYLOY: Launched in 9 countries, with approvals in 38 countries including recent approval in China

PADCEV: First-line mUC indication shows strong uptake with approvals in 16 countries

Booked ¥180.5 billion impairment losses on intangible assets including IZERVAY ex-U.S. (¥115.1 billion), AT466 (¥51.8 billion), and iota (¥8 billion)

Strategic Focus

SMT initiatives progressing toward FY'24 target of ¥40 billion in cost optimization

R&D portfolio optimization: terminated seven programs and dissolved Primary Focus candidate "immune homeostasis"

Increasing resources to high-priority assets including late-stage development of flagship programs

Focus on business development opportunities for derisked assets in later stages

Management structure changes announced to enhance speed from R&D to launch

FY2025 Outlook

funding ocular

The company remains focused on building sustainable growth beyond XTANDI loss of exclusivity expected in 2027.